Depsides and depsidones
Medchemexpress LLC Phenyl salicylate (standard) | 118-55-8 | 100.0% | 250 MG
Phenyl salicylate (Standard) is the analytical standard of Phenyl salicylate. This product is intended for research and analytical applications, and exhibits antibacterial activity when hydrolyzed in the small intestine. It is often used as a nervous system inhibitor and intestinal preservative.
- Analytical standard for research and analytical applications
- Exhibits antibacterial activity
- Functions as a nervous system inhibitor
- Serves as an intestinal preservative
- Used in qualitative, quantitative, and methodological research experiments including HPLC, GC, and MS
Medchemexpress LLC SOR-C13 | 1187852-48-7 | 99.1% | 1565.81 | 10 MG
SOR-C13 is a carboxy-terminal truncated peptide that acts as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. It exhibits anticancer activity by targeting TRPV6, a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer.
- High-affinity TRPV6 antagonist with an IC50 value of 14 nM
- Demonstrates anticancer activity
- Targets TRPV6, a non-voltage gated calcium channel
- Effectively inhibits tumor growth in relevant animal models
Medchemexpress LLC Sor-c13 TFA | 1187852-48-7 | 99.3% | 1565.81 | 25 MG
SOR-C13 TFA is a carboxy-terminal truncated peptide. It functions as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA exhibits anticancer activity.
- High-affinity TRPV6 antagonist with an IC50 value of 14 nM.
- Associated with malignancy and poor prognosis in breast cancer.
- Exhibits anticancer activity.
- For research use only.
- Not for sale to patients.
Medchemexpress LLC Sor-C13 Tfa | 99.3% | 1565.81 (free acid) | 10 MG
SOR-C13 TFA is a carboxy-terminal truncated peptide that acts as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. It has shown anticancer activity and targets TRPV6, a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer.
- High-affinity TRPV6 antagonist
- Exhibits anticancer activity
- Targets non-voltage gated calcium channel TRPV6
- Potentially useful in breast cancer research